Published in Neuropsychopharmacology on December 31, 2015
Sex Differences in Midbrain Dopamine D2-Type Receptor Availability and Association with Nicotine Dependence. Neuropsychopharmacology (2016) 0.75
Models for longitudinal data: a generalized estimating equation approach. Biometrics (1988) 27.90
Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med (1994) 6.75
Doses of nicotine and lung carcinogens delivered to cigarette smokers. J Natl Cancer Inst (2000) 6.01
Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature (2011) 3.77
Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res (2008) 2.72
Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther (1984) 2.43
Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther (2006) 2.35
Saliva cotinine levels in smokers and nonsmokers. Am J Epidemiol (2000) 2.28
Aversion to nicotine is regulated by the balanced activity of β4 and α5 nicotinic receptor subunits in the medial habenula. Neuron (2011) 2.23
Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) (2004) 2.07
Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)₂α5 AChR function. Mol Pharmacol (2010) 2.02
Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology (Berl) (2000) 1.76
Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology (2007) 1.74
Smokers' sex and the effects of tobacco cigarettes: subject-rated and physiological measures. Nicotine Tob Res (1999) 1.57
Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. J Pharmacol Exp Ther (2010) 1.57
Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology (Berl) (1997) 1.45
The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther (1991) 1.39
High reinforcing efficacy of nicotine in non-human primates. PLoS One (2007) 1.29
The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl) (2012) 1.22
Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) (2000) 1.16
Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol (2002) 1.16
Sex differences in nicotine action. Handb Exp Pharmacol (2009) 1.08
Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav (1983) 1.07
Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J Pharmacol Exp Ther (1990) 1.04
Nicotine consumption is regulated by a human polymorphism in dopamine neurons. Mol Psychiatry (2013) 1.03
Subjective, physiological, and cognitive responses to intravenous nicotine: effects of sex and menstrual cycle phase. Neuropsychopharmacology (2013) 0.97
Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav (1983) 0.97
Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers. Psychopharmacology (Berl) (1996) 0.95
Sex differences in nicotine self-administration in rats during progressive unit dose reduction: implications for nicotine regulation policy. Pharmacol Biochem Behav (2013) 0.94
Smoke yield of cigarettes and puffing behavior in men and women. Psychopharmacology (Berl) (1982) 0.94
Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. J Womens Health Gend Based Med (2002) 0.93
Individual variability in responses to nicotine. Behav Genet (1995) 0.93
Nicotine yield as determinant of smoke exposure indicators and puffing behavior. Pharmacol Biochem Behav (1991) 0.85
A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. Neuropsychopharmacology (2015) 0.85
FKBP5 variation is associated with the acute and chronic effects of nicotine. Pharmacogenomics J (2014) 0.81